CVKD (Cadrenal Therapeutics) Other Current Assets: $0.54 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CVKD Cadrenal Therapeutics Inc CVKD
26 GF Score
Price $2.03
! 2 Warning Signs
View Full Analysis

What is Cadrenal Therapeutics Other Current Assets?

Cadrenal Therapeutics CVKD +2.01% 26 Other Current Assets is $0.54 Mil as of Mar. 2026. GuruFocus rates CVKD with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Cadrenal Therapeutics's other current assets for the quarter that ended in Mar. 2026 was $0.54 Mil.

Cadrenal Therapeutics's quarterly other current assets increased from Sep. 2025 ($0.21 Mil) to Dec. 2025 ($0.31 Mil) and increased from Dec. 2025 ($0.31 Mil) to Mar. 2026 ($0.54Mil).

Cadrenal Therapeutics's annual other current assets increased from Dec. 2023 ($0.05 Mil) to Dec. 2024 ($0.06 Mil) increased from Dec. 2024 ($0.06 Mil) to Dec. 2025 ($0.31 Mil).


Cadrenal Therapeutics Other Current Assets Related Terms


Cadrenal Therapeutics Other Current Assets Historical Data

* Premium members only.

The historical data trend for Cadrenal Therapeutics's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cadrenal Therapeutics Other Current Assets Chart

Cadrenal Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Current Assets
0.70 0.05 0.06 0.31

Cadrenal Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.38 0.21 0.31 0.54
CVKD
26GF Score
Cadrenal Therapeutics Inc CVKD
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cadrenal Therapeutics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $0.54 Mil mean?
Cadrenal Therapeutics (CVKD) has a Other Current Assets of $0.54 Mil as of Mar. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Cadrenal Therapeutics.
Is Cadrenal Therapeutics' Other Current Assets too high?
Cadrenal Therapeutics' current Other Current Assets is $0.54 Mil. Overall, Cadrenal Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Cadrenal Therapeutics' Other Current Assets compare to RVPH and IMNN?
Cadrenal Therapeutics' Other Current Assets of $0.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Cadrenal Therapeutics. Cadrenal Therapeutics's current Other Current Assets is $0.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cadrenal Therapeutics stock overvalued right now?
Cadrenal Therapeutics (CVKD) has a current Other Current Assets of $0.54 Mil. The current Other Current Assets is $0.54 Mil. Cadrenal Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Cadrenal Therapeutics (CVKD), the current Other Current Assets is $0.54 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cadrenal Therapeutics Business Description

Address 822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
26GF Score

Get the complete analysis for CVKD

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.03
Price